These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 25711670)

  • 1. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
    Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
    Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis.
    Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kartashov AV; Kurbatova KA; Gorodokin GI; Novik AA
    Exp Hematol; 2012 Nov; 40(11):892-8. PubMed ID: 22771495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.
    Mancardi GL; Sormani MP; Di Gioia M; Vuolo L; Gualandi F; Amato MP; Capello E; Currò D; Uccelli A; Bertolotto A; Gasperini C; Lugaresi A; Merelli E; Meucci G; Motti L; Tola MR; Scarpini E; Repice AM; Massacesi L; Saccardi R;
    Mult Scler; 2012 Jun; 18(6):835-42. PubMed ID: 22127896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis.
    Shevchenko YL; Novik AA; Kuznetsov AN; Afanasiev BV; Lisukov IA; Kozlov VA; Rykavicin OA; Ionova TI; Melnichenko VY; Fedorenko DA; Kulagin AD; Shamanski SV; Ivanov RA; Gorodokin G
    Exp Hematol; 2008 Aug; 36(8):922-8. PubMed ID: 18468768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
    Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
    Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
    Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R;
    JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
    Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
    Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
    Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
    Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS.
    Saiz A; Carreras E; Berenguer J; Yagüe J; Martínez C; Marín P; Rovira M; Pujol T; Arbizu T; Graus F
    Neurology; 2001 Apr; 56(8):1084-9. PubMed ID: 11320183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
    Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
    Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.
    Fassas A; Passweg JR; Anagnostopoulos A; Kazis A; Kozak T; Havrdova E; Carreras E; Graus F; Kashyap A; Openshaw H; Schipperus M; Deconinck E; Mancardi G; Marmont A; Hansz J; Rabusin M; Zuazu Nagore FJ; Besalduch J; Dentamaro T; Fouillard L; Hertenstein B; La Nasa G; Musso M; Papineschi F; Rowe JM; Saccardi R; Steck A; Kappos L; Gratwohl A; Tyndall A; Samijn J;
    J Neurol; 2002 Aug; 249(8):1088-97. PubMed ID: 12195460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role and place of high-dose immunosuppressive therapy and autologous transplantation of hematopoietic stem cells for autoimmune diseases].
    Makarov SV; Rossiev VA; Mishchenko OV; Kozlov VA; Semagina OV; Alexandrova IY; Grishina GV; Minaev YL
    Ter Arkh; 2016; 88(1):53-59. PubMed ID: 26978610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis].
    Saiz A; Blanco Y; Berenguer J; Gómez-Choco M; Carreras E; Arbizu T; Graus F
    Neurologia; 2008 Sep; 23(7):405-7. PubMed ID: 18726717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
    JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.
    Mancardi GL; Sormani MP; Gualandi F; Saiz A; Carreras E; Merelli E; Donelli A; Lugaresi A; Di Bartolomeo P; Rottoli MR; Rambaldi A; Amato MP; Massacesi L; Di Gioia M; Vuolo L; Currò D; Roccatagliata L; Filippi M; Aguglia U; Iacopino P; Farge D; Saccardi R; ;
    Neurology; 2015 Mar; 84(10):981-8. PubMed ID: 25672923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
    Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
    Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.
    Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stüve O; Arnold DL; Spychala ME; McConville KC; Harris KM; Phippard D; Georges GE; Wundes A; Kraft GH; Bowen JD
    JAMA Neurol; 2015 Feb; 72(2):159-69. PubMed ID: 25546364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up more than 10 years after HSCT: a monocentric experience.
    Frau J; Carai M; Coghe G; Fenu G; Lorefice L; La Nasa G; Mamusa E; Vacca A; Marrosu MG; Cocco E
    J Neurol; 2018 Feb; 265(2):410-416. PubMed ID: 29270686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients.
    Carreras E; Saiz A; Marín P; Martínez C; Rovira M; Villamor N; Aymerich M; Lozano M; Fernández-Avilés F; Urbano-Izpizua A; Montserrat E; Graus F
    Haematologica; 2003 Mar; 88(3):306-14. PubMed ID: 12651270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.